DSM Biologics scaling-up
DSM is building a large-scale biopharmaceuticals plant in Montreal, Canada, with the construction of the new multi-product facility, that will ultimately feature four fermentors with a combined capacity of more than 60,000 litres and full downstream processing capabilities with the necessary infrastructure.
DSM is building a large-scale biopharmaceuticals plant in Montreal, Canada, with the construction of the new multi-product facility, that will ultimately feature four fermentors with a combined capacity of more than 60,000 litres and full downstream processing capabilities with the necessary infrastructure.
The facility will be used for the production of monoclonal antibodies (MABs) and recombinant proteins based on mammalian cell culture technology. These are a new generation of drugs representing the most promising and strongly growing segment of the pharmaceutical industry.
The plant has a modular design, with separated production lines and will be built in two phases. Phase one of the project features the construction of the full shell with all necessary infrastructure and the installation of the initial 30,000 litres lines. It is expected that this part of the new facility will come on stream by mid 2005. The investment for this first phase is approximately €100m (US$117m).
'The small and large scale manufacturing of DSM Biologics in Groningen (the Netherlands) and Montreal (Canada) and the matching facilities for sterile dosage forms at DSM Pharmaceuticals Inc. (Greenville, North Carolina, US) represent a unique and comprehensive range of services provided by DSM, thereby strengthening DSM's leading position as a supplier to the pharma industry,' said Feike Sijbesma, member of the Managing Board of DSM.